The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Matt McNally is rejoining Publicis. The ad exec has taken the global CEO post at Publicis Health, returning to a company ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...

BD is banging the drum for self-collection of cervical cancer screening samples again. | BD is banging the drum for ...

Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Mendaera has found a leader with deep medical robotics experience to lead its commercialization push. Eric Davidson has taken ...